Another Clinical Trial for an MDS Drug

Posted on June 28, 2006 by David Austin

From a press release from the company...

Lorus Therapeutics Inc. ('Lorus'), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, today announced a plan for a new clinical investigation of GTI-2040 as a single-agent in patients with high grade myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

Source:  Yahoo News

Tags:
Trackbacks (0) Links to blogs that reference this article Trackback URL
http://www.benzeneleukemialawblog.com/admin/trackback/59067
Comments (0) Read through and enter the discussion with the form at the end
Post A Comment / Question Use this form to add a comment to this entry.







Remember personal info?
Send To A Friend Use this form to send this entry to a friend via email.